Related Experiment Video
Updated: Jul 5, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Polymer conjugates as therapeutics: future trends, challenges and opportunities
María J Vicent1, Lucile Dieudonné, Rodrigo J Carbajo
1Centro de Investigación Príncipe Felipe, Polymer Therapeutics Laboratory, Avenue Autopista del Saler 16, E-46012 Valencia, Spain. mjvicent@cipf.es
Polymer conjugates are advancing medical treatments, with many polymer-drug conjugates in clinical trials. Future research will focus on new anticancer agents, materials, and non-cancer disease applications for enhanced therapeutic value.
Area of Science:
- Polymer chemistry and medicinal chemistry
Background:
- Polymer conjugates have demonstrated clinical proof of concept over 30 years.
- Marketed polymer-protein conjugates and numerous polymer-drug conjugates in clinical trials highlight platform success.
Purpose of the Study:
- To present the latest advances and future trends in polymer conjugate technology.
- To explore the potential of polymer conjugates in clinical applications and research.
Main Methods:
- Focus on novel anticancer agents and targeted delivery strategies.
- Development of advanced polymeric materials with defined architectures.
- Exploration of therapeutic applications beyond cancer treatment.
Main Results:
- Polymer conjugates offer significant potential for developing novel therapeutics.
- The field is characterized by rapidly growing opportunities and ongoing clinical investigations.
Conclusions:
- Polymer therapeutics represent a rapidly emerging field with substantial potential.
- This platform technology offers enhanced therapeutic value and diverse research avenues.
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Microorganisms in Medicine and Therapeutics
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Phase II Conjugation Reactions: Overview
Modified-Release Drug Delivery Systems: Site-Targeted
